Contact
searchSearch
HMP Global
Login

Follicular Lymphoma Resource Center

Headshots
Interview
Transforming FL Treatment: Inside the EPCORE FL-1 Trial Results
09/30/2025
Brian Elliott; Al Fakhoury, PharmD, RPh
AbbVie’s Al Fakhoury, PharmD, and Genmab’s Brian Elliott, MD, share how the EPCORE FL-1 trial results position epcoritamab + R2 as a chemo-free, highly effective option poised to shift the treatment paradigm in follicular lymphoma.
AbbVie’s Al Fakhoury, PharmD, and Genmab’s Brian Elliott, MD, share how the EPCORE FL-1 trial results position epcoritamab + R2 as a chemo-free, highly effective option poised to shift the treatment paradigm in follicular lymphoma.
AbbVie’s Al Fakhoury, PharmD,...
09/30/2025
Journal of Clinical Pathways
FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
From Oncology
News
Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma
01/15/2024
Jordan Kadish
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene...
01/15/2024
Oncology
From Oncology
Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
News
Yttrium-90 Ibritumomab Tiuxetan Among Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma
05/17/2022
Ellen Kurek
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life...
05/17/2022
Journal of Clinical Pathways
John Burke, MD
Videos
Analysis of Online Treatment Decision Tool Reveals Variation in FL Management Between Experts and Oncology HCPs
03/22/2022
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses...
03/22/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Matthew Matasar, MD
Videos
Health Care Resource Utilization and Costs Among Patients With FL Receiving Multiple Lines of Therapy
12/15/2021
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses...
12/15/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Obinutuzumab for the Treatment of FL
09/23/2021
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the...
09/23/2021
Journal of Clinical Pathways
News
Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
05/06/2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of...
05/06/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for B-Cell Lymphomas
03/17/2021
Janelle Bradley
The National Comprehensive Cancer Network update of these guidelines covers follicular lymphoma.
The National Comprehensive Cancer Network update of these guidelines covers follicular lymphoma.
The National Comprehensive...
03/17/2021
Journal of Clinical Pathways

Expert Insights

Headshots
Interview
Transforming FL Treatment: Inside the EPCORE FL-1 Trial Results
09/30/2025
Brian Elliott; Al Fakhoury, PharmD, RPh
AbbVie’s Al Fakhoury, PharmD, and Genmab’s Brian Elliott, MD, share how the EPCORE FL-1 trial results position epcoritamab + R2 as a chemo-free, highly effective option poised to shift the treatment paradigm in follicular lymphoma.
AbbVie’s Al Fakhoury, PharmD, and Genmab’s Brian Elliott, MD, share how the EPCORE FL-1 trial results position epcoritamab + R2 as a chemo-free, highly effective option poised to shift the treatment paradigm in follicular lymphoma.
AbbVie’s Al Fakhoury, PharmD,...
09/30/2025
Journal of Clinical Pathways
Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
John Burke, MD
Videos
Analysis of Online Treatment Decision Tool Reveals Variation in FL Management Between Experts and Oncology HCPs
03/22/2022
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses...
03/22/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Matthew Matasar, MD
Videos
Health Care Resource Utilization and Costs Among Patients With FL Receiving Multiple Lines of Therapy
12/15/2021
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses...
12/15/2021
Journal of Clinical Pathways
Videos
Study Highlights Need to Minimize Health Care Costs in FL
11/29/2020
Nathan Fowler, MD, MD Anderson Cancer Center, discusses results from a study which explored treatment patterns and health care costs in commercially insured patients with FL.
Nathan Fowler, MD, MD Anderson Cancer Center, discusses results from a study which explored treatment patterns and health care costs in commercially insured patients with FL.
Nathan Fowler, MD, MD Anderson...
11/29/2020
Journal of Clinical Pathways
ENGAGING EXPERTS
Treatment Options for Patients With Relapsed/Refractory FL
10/15/2020
10/15/2020
Journal of Clinical Pathways
ENGAGING EXPERTS
Assessing Response to Follicular Lymphoma Treatment
09/24/2020
09/24/2020
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Woyach Headshot
Interview
Targeting BTK Mutations in CLL: Emerging Data on Rocbrutinib
12/18/2025
Jennifer Ann Woyach, MD
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early...
12/18/2025
Journal of Clinical Pathways
Joanna Rhodes, MD, MSCE
Interview
Transforming CLL Management: How MRD Could Shape Treatment Duration and Decision-Making
12/17/2025
Joanna M. Rhodes, MD, MSCE
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion,...
12/17/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
12/15/2025
Youngmin Kwon
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral...
12/15/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice
12/04/2025
Houda Hachad, PharmD
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing...
12/04/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Breaking Down Cancer Prevention: What Really Works?
11/26/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down...
11/26/2025
Cancer Care Business Exchange
Koulopoulos
Videos
Gigatrends Reshaping Global Health Care: Insights for CPC+CBEx 2025
10/31/2025
Thomas Koulopoulos
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos...
10/31/2025
Journal of Clinical Pathways
Kwon Headshot
Interview
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
10/23/2025
Youngmin Kwon
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin...
10/23/2025
Journal of Clinical Pathways
CONFERENCE COVERAGE
CAR T-Cell Therapy and Bispecifics in the Community: Opportunities and Obstacles
10/22/2025
Lavi Kwiatkowsky
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi...
10/22/2025
Journal of Clinical Pathways

Newsfeed

FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
News
Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma
01/15/2024
Jordan Kadish
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene...
01/15/2024
Oncology
News
Yttrium-90 Ibritumomab Tiuxetan Among Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma
05/17/2022
Ellen Kurek
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life...
05/17/2022
Journal of Clinical Pathways
News
Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
05/06/2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of...
05/06/2021
Journal of Clinical Pathways
Conference Coverage
Rituximab Monotherapy Extends TTNT vs Observation in Advanced FL
12/11/2020
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Rituximab monotherapy improves...
12/11/2020
Journal of Clinical Pathways
Clinical Pathways NEXT, Free Webinar, CPC, Oncology Pathways
Press Release
HMP Global Launches Clinical Pathways NEXT to Address Real-Time Oncology Pathway Decision-Making
02/03/2026
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation...
02/03/2026
Journal of Clinical Pathways
News
Adoptive Cell Therapy Advances Target Ovarian Cancer Solid Tumor Barriers
01/23/2026
Hannah Musick
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review...
01/23/2026
Journal of Clinical Pathways
News
Medicare Advantage Reduces Use of High-Cost Cancer Drugs Compared With Traditional Medicare
01/22/2026
Lisa Kuhns, PhD, MD
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA)...
01/22/2026
Journal of Clinical Pathways
News
Medicare Advantage Linked to Lower Access to High-Quality Cancer Surgery in US
01/19/2026
Grace Taylor, MS, MA
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found...
01/19/2026
Journal of Clinical Pathways
News
McKesson Report Details Key Trends Shaping US Community Oncology Care
01/14/2026
Grace Taylor, MS, MA
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community...
01/14/2026
Journal of Clinical Pathways
News
2025 US Cancer Disparities Report Highlights Education, Rural Gaps
01/12/2026
Hannah Musick
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s...
01/12/2026
Journal of Clinical Pathways
News
Real-World Data Show Similar Outcomes for First-Line uHCC Immunotherapy Regimens
01/08/2026
Grace Taylor, MS, MA
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer...
01/08/2026
Journal of Clinical Pathways
News
CAR T Therapy Access Remains Uneven Despite Specialist Referral
01/07/2026
Grace Taylor, MS, MA
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred...
01/07/2026
Journal of Clinical Pathways
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
Conference Coverage
Biology-Based Strategies for Managing Iron Toxicity in Hematologic Disorders
12/19/2025
Grace Taylor, MS, MA
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology...
12/19/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of Obinutuzumab for the Treatment of FL
09/23/2021
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the...
09/23/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use